The Swiss drug company Roche announced last week that it is stepping away from research in RNA interference, a popular approach to medical therapies and one that Roche has poured more than $400 million into over 3 years.
No takes yet. Share an insight, caveat, or question.
Jennifer Couzin-Frankel (2010) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: